StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
ZS Pharma (ZSPH) Reports Interim Results From Long-Term Safety Study of ZS-9
November 9, 2015 7:14 AM
ZS Pharma, Inc. (Nasdaq: ZSPH) presented interim results from ZS005, a long-term safety and efficacy study of ZS-9 (sodium zirconium ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
JPMorgan Downgrades ZS Pharma (ZSPH) to Neutral
November 9, 2015 7:17 AM
ZS Pharma Announces Positive Interim Results From a Long-Term Safety Study of ZS-9
November 7, 2015 1:00 PM